THE European Medicines Agency (EMA) has followed the US Food and Drug Administration (FDA) in granting approval for the use of Pfizer's COVID-19 vaccine (COVAX) in children aged five to 11 years.
The EMA confirmed that the dose regime would see children receive lower doses of the vaccine than people aged 12 years and older (10 g compared with 30 g).
The Therapeutic Goods Administration (TGA) had granted a provisional determination for a similar approval of the shot last month.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Nov 21
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Nov 21
